Bronze
Biometrix Technology. Inc. has developed theworld’s first 9G technology that arranges 9 guanine bases at regular intervalsin a molecular recognition format and DAGON technology that can detect markerproteins up to a pg/ml level. Based on this core technology, we have establisheda platform technology applicable to the detection of various genes andproteins, and based on this, we sell IVD diagnostic devices and reagents. Usingthis technology, Biometrix Technology has entered into the market forcardiovascular disease prevention and management by using cardiovascularmonitoring products to easily manage cardiovascular diseases. In addition, weare working hard to lead the field of early cancer screening moleculardiagnostics that no one has entered the market yet. Biometrix Technologycontinues to showcase the world’s leading cardiovascular and early-stage cancermolecular diagnostic reagents and hopes to become the world’s leadingprofessional healthcare company.